CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about data from RESONATE-2 showing sustained progression-free and overall survival in patients with chronic lymphocytic leukemia being treated with ibrutinib in the frontline setting.
A phase 1 trial of the investigational agent CLN-081 indicates antitumor activity coupled with a tolerable safety profile as treatment of patients with non–small cell lung cancer and EGFR exon 20 insertion mutations.
Two-year efficacy and safety data from a pivotal trial of nivolumab/ipilimumab plus chemotherapy as treatment of non–small cell lung cancer support the continued use of the combination.
Regardless of primary tumor site or disease stage, avelumab maintenance was able to elicit overall survival benefit versus best supportive care for platinum-treated urothelial cancer.
Data presented at the 2021 ASCO Annual Meeting from the phase 3 PACIFIC trial show long-term survival benefit for patients with unresectable stage III non–small cell lung cancer treated with durvalumab following chemoradiotherapy.
Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.
High rates of durable complete responses are reported at the 2021 ASCO Annual Meeting with ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma.
Phase 1/2 data presented at the 2021 ASCO Annual Meeting for the novel PSMA-targeting agent HPN424 show tumor responses in patients with pretreated metastatic castration-resistant prostate cancer.
A positive efficacy and safety profile persists with pralsentinib in RET fusion–positive non–small cell lung cancer, according to data presented at the 2021 ASCO Annual Meeting.
The CAR T-cell product idecabtagene vicleucel in patients with heavily pretreated multiple myeloma continued to show benefit of therapy at a median follow-up of 24.8 months.
Data presented at the 2021 ASCO Annual Meeting on 3 prominent trials of niraparib as maintenance for ovarian cancer after a positive response to platinum-based chemotherapy further support the use of the agent in multiple settings.
Phase 2 data presented at the 2021 ASCO Annual Meeting indicate that more than half of patients with previously treated advanced colorectal cancer who were treated with pembrolizumab plus lenvatinib were alive at 6 months.
Data from the KEYNOTE-564 trial presented at ASCO indicate benefit of pembrolizumab therapy in patients with clear cell renal cell carcinoma who were receiving therapy in the adjuvant setting.
Awaited outcomes of the phase 3 OUTBACK trial presented at the 2021 ASCO Annual Meeting do not indicate benefit of adjuvant chemotherapy for patients with cervical cancer.
CancerNetwork® sat down with Stephen V. Liu, MD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about pralsetinib for patients with non–small cell lung cancer harboring RET fusions and adequate biomarker testing in the frontline.
Results of the phase 3 JUPITER-02 trial presented at ASCO 2021 support the use of toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma.
Survival outcomes improved when nivolumab was added to either ipilimumab or chemotherapy versus chemotherapy alone in advanced/metastatic esophageal squamous cell carcinoma
Data from the OlympiA trial support olaparib use in certain patients with BRCA1/2–positive early breast cancer.
A 40% reduction in the risk of death was observed when 177Lu-PSMA-617A was added to standard of care therapy in patients with PSMA-positive metastatic castration-resistant prostate cancer.
A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.
According to new research, patients with chronic lymphocytic leukemia may have suboptimal antibody-mediated response with COVID-19 vaccination.
Based on positive phase 3 results, a new drug application for sugemalimab to treat patients with locally advanced or unresectable stage III non–small cell lung cancer will likely be submitted to the FDA.
The results from a retrospective trial that found stereotactic radiosurgery produced comparable results for both brainstem metastases and nonbrainstem brain metastases suggest both groups of patients should be eligible for stereotactic radiosurgery clinical trials.
Patients who underwent advanced molecular imaging had higher rates of disease-free survival, according to new research.
Based on data from a phase 1 trial, the FDA granted breakthrough therapy designation to teclistamab for certain patients with pretreated multiple myeloma.
The priority review designation for pacritinib is based off results from 3 trials investigating pacritinib 200 mg twice daily for patients with myelofibrosis and severe thrombocytopenia.
Look back at some of the important news and notes from last week you might have missed in the world of oncology from the FDA and the journal ONCOLOGY®.
A retrospective analysis aims to define treatment outcomes in patients with mantle cell lymphoma who are elderly or unfit for standard therapy.
Based on phase 3 data, plinabulin plus granulocyte colony-stimulating factor is being considered by the FDA for the prevention of chemotherapy-induced neutropenia.
A 3-year follow-up analysis of event-free and overall survival revealed similar results for patients with stage II or III ERBB2-positive breast cancer treated with either neoadjuvant anthracycline and nonanthracycline treatment regimens.
